Revenues of Cytek Biosciences, Inc. from 30 Jun 2020 to 30 Sep 2024

Taxonomy & unit: us-gaap: USD
Description: Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).
Summary: Cytek Biosciences, Inc. quarterly and annual Revenues in USD history and change rate from 30 Jun 2020 to 30 Sep 2024.
Cytek Biosciences, Inc. Revenues for the quarter ending 30 Sep 2024 was $51,500,000, a 7.3% increase year-over-year.
Cytek Biosciences, Inc. Revenues for the twelve months ending 30 Sep 2024 was $201,211,000, a 813% increase year-over-year.
Cytek Biosciences, Inc. annual Revenues for 2023 was $193,015,000, a 6414% increase from 2022.
Cytek Biosciences, Inc. annual Revenues for 2022 was $2,963,000, a 36% increase from 2021.
Cytek Biosciences, Inc. annual Revenues for 2021 was $2,181,000, a 207% increase from 2020.
Source SEC data: View on sec.gov

Revenues, Trailing 12 Months (USD)

Revenues, Quarterly (USD)

Revenues, YoY Quarterly Change (%)

Revenues, Annual (USD)

Revenues, YoY Annual Change (%)

Cytek Biosciences, Inc. Quarterly Revenues (USD)

Period	TTM Value	Value	YoY Chg	Change %	Start Date	End Date	Report	Filed	Fiscal Year	Fiscal Period
Q3 2024	$201,211,000	$51,500,000	+$3,500,000	+7.3%	01 Jul 2024	30 Sep 2024	10-Q	07 Nov 2024	2024	Q3
Q2 2024	$197,711,000	$46,617,000	-$3,076,000	-6.2%	01 Apr 2024	30 Jun 2024	10-Q	06 Aug 2024	2024	Q2
Q1 2024	$200,787,000	$44,860,000	+$7,772,000	+21%	01 Jan 2024	31 Mar 2024	10-Q	08 May 2024	2024	Q1
Q4 2023	$193,015,000	$58,234,000	+$170,971,000		01 Oct 2023	31 Dec 2023	10-K	13 Mar 2024	2023	FY
Q3 2023	$22,044,000	$48,000,000	+$7,523,000	+19%	01 Jul 2023	30 Sep 2023	10-Q	07 Nov 2024	2024	Q3
Q2 2023	$14,521,000	$49,693,000	+$9,534,000	+24%	01 Apr 2023	30 Jun 2023	10-Q	06 Aug 2024	2024	Q2
Q1 2023	$4,987,000	$37,088,000	+$2,024,000	+5.8%	01 Jan 2023	31 Mar 2023	10-Q	08 May 2024	2024	Q1
Q4 2022	$2,963,000	$112,737,000	-$25,862,000	-30%	01 Oct 2022	31 Dec 2022	10-K	13 Mar 2024	2023	FY
Q3 2022	$28,825,000	$40,477,000	+$6,101,000	+18%	01 Jul 2022	30 Sep 2022	10-Q	14 Nov 2023	2023	Q3
Q2 2022	$22,724,000	$40,159,000	+$9,751,000	+32%	01 Apr 2022	30 Jun 2022	10-Q	08 Aug 2023	2023	Q2
Q1 2022	$12,973,000	$35,064,000	+$10,792,000	+44%	01 Jan 2022	31 Mar 2022	10-Q	09 May 2023	2023	Q1
Q4 2021	$2,181,000	$86,875,000			01 Oct 2021	31 Dec 2021	10-K	13 Mar 2024	2023	FY
Q3 2021		$34,376,000	+$9,280,000	+37%	01 Jul 2021	30 Sep 2021	10-Q	09 Nov 2022	2022	Q3
Q2 2021		$30,408,000	+$11,272,000	+59%	01 Apr 2021	30 Jun 2021	10-Q	10 Aug 2022	2022	Q2
Q1 2021		$24,272,000			01 Jan 2021	31 Mar 2021	10-Q	12 May 2022	2022	Q1
Q3 2020		$25,096,000			01 Jul 2020	30 Sep 2020	10-Q	12 Nov 2021	2021	Q3
Q2 2020		$19,136,000			01 Apr 2020	30 Jun 2020	10-Q	03 Sep 2021	2021	Q2

Period	Value	YoY Chg	Change %	Start Date	End Date	Report	Filed	Fiscal Year	Fiscal Period
2023	$193,015,000	+$190,052,000	+6414%	01 Jan 2023	31 Dec 2023	10-K	13 Mar 2024	2023	FY
2022	$2,963,000	+$782,000	+36%	01 Jan 2022	31 Dec 2022	10-K	13 Mar 2024	2023	FY
2021	$2,181,000	+$1,471,000	+207%	01 Jan 2021	31 Dec 2021	10-K	13 Mar 2024	2023	FY
2020	$710,000			01 Jan 2020	31 Dec 2020	10-K	01 Mar 2023	2022	FY

* An asterisk sign (*) next to the value indicates that the value is likely invalid.